PHXM
Income statement / Annual
Last year (2023), PHAXIAM Therapeutics S.A.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, PHAXIAM Therapeutics S.A.'s net income was -$23.49 M.
See PHAXIAM Therapeutics S.A.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$5.28 M |
$0.00 |
$3.36 M |
$19.72 M |
$10.78 M |
$4.37 M |
| Cost of Revenue |
$1.61 M
|
$2.91 M
|
$5.38 M
|
$4.99 M
|
$4.22 M
|
$797.00 K
|
$530.00 K
|
$19.72 M
|
$10.78 M
|
$4.37 M
|
| Gross Profit |
-$1.61 M
|
-$2.91 M
|
-$5.38 M
|
-$4.99 M
|
$1.07 M
|
-$33.47 M
|
-$25.46 M
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0.2
|
0
|
-7.57
|
0
|
0
|
0
|
| Research and Development Expenses |
$9.84 M
|
$15.92 M
|
$40.22 M
|
$53.28 M
|
$52.19 M
|
$33.47 M
|
$25.46 M
|
$19.53 M
|
$10.53 M
|
$2.24 M
|
| General & Administrative Expenses |
$0.00
|
$13.89 M
|
$15.10 M
|
$14.97 M
|
$17.16 M
|
$14.60 M
|
$8.79 M
|
$6.66 M
|
$7.62 M
|
$4.36 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$13.97 M
|
$13.89 M
|
$15.10 M
|
$14.97 M
|
$17.16 M
|
$14.60 M
|
$8.79 M
|
$6.66 M
|
$7.62 M
|
$4.36 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$493.00 K
|
| Operating Expenses |
$23.81 M
|
$27.15 M
|
$56.52 M
|
$68.83 M
|
$69.36 M
|
$48.07 M
|
$34.25 M
|
$25.78 M
|
$18.14 M
|
$4.58 M
|
| Cost And Expenses |
$25.42 M
|
$32.08 M
|
$60.70 M
|
$68.83 M
|
$69.36 M
|
$48.07 M
|
$34.25 M
|
$22.39 M
|
$15.58 M
|
$8.95 M
|
| Interest Income |
$259.00 K
|
$4.45 M
|
$13.00 K
|
$889.00 K
|
$2.95 M
|
$163.00 K
|
$539.00 K
|
$545.00 K
|
$0.00
|
$0.00
|
| Interest Expense |
$196.00 K
|
$1.36 M
|
$2.14 M
|
$5.35 M
|
$1.53 M
|
$9.00 K
|
$3.18 M
|
$4.00 K
|
$5.00 K
|
$6.80 K
|
| Depreciation & Amortization |
$1.61 M
|
$2.91 M
|
$5.38 M
|
$4.99 M
|
-$2.95 M
|
-$9.06 M
|
$530.00 K
|
$427.00 K
|
$288.00 K
|
$250.24 K
|
| EBITDA |
-$23.81 M |
-$22.69 M |
-$47.46 M |
-$67.94 M |
$5.28 M |
-$47.27 M |
-$33.72 M |
-$25.78 M |
-$15.25 M |
-$10.72 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
1
|
0
|
-10.02
|
-1.31
|
-1.41
|
-2.45
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
1
|
0
|
-9.18
|
-1.33
|
-1.71
|
-2.05
|
| Total Other Income/Expenses Net |
$683.00 K
|
$32.38 M
|
$2.72 M
|
-$747.00 K
|
-$67.94 M
|
$5.40 M
|
-$2.64 M
|
$4.31 M
|
-$1.65 M
|
-$1.46 M
|
| Income Before Tax |
-$24.73 M
|
$293.00 K
|
-$53.80 M
|
-$73.30 M
|
-$62.66 M
|
-$38.22 M
|
-$33.53 M
|
-$21.90 M
|
-$17.24 M
|
-$10.40 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
-11.86
|
0
|
-9.97
|
-1.11
|
-1.6
|
-2.38
|
| Income Tax Expense |
-$1.25 M
|
$521.00 K
|
$2.00 K
|
$3.00 K
|
-$1.00 K
|
$2.00 K
|
-$3.00 K
|
$10.00 K
|
-$2.22 M
|
-$1.54 M
|
| Net Income |
-$23.49 M
|
-$227.00 K
|
-$53.80 M
|
-$73.30 M
|
-$62.66 M
|
-$38.22 M
|
-$33.53 M
|
-$21.91 M
|
-$15.01 M
|
-$8.86 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
-11.86
|
0
|
-9.97
|
-1.11
|
-1.39
|
-2.03
|
| EPS |
-4.62 |
-0.1 |
-22.7 |
-36.55 |
-3.49 |
-2.13 |
-1.87 |
-2.74 |
-2.16 |
-1.51 |
| EPS Diluted |
-4.62 |
-0.1 |
-22.7 |
-36.55 |
-3.49 |
-2.13 |
-1.87 |
-2.74 |
-2.16 |
-1.51 |
| Weighted Average Shares Out |
$5.08 M
|
$3.10 M
|
$2.37 M
|
$2.01 M
|
$1.94 M
|
$1.94 M
|
$1.23 M
|
$7.98 M
|
$6.96 M
|
$5.88 M
|
| Weighted Average Shares Out Diluted |
$5.08 M
|
$3.10 M
|
$2.37 M
|
$2.01 M
|
$1.94 M
|
$1.94 M
|
$1.23 M
|
$7.98 M
|
$6.96 M
|
$5.88 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
